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Understanding the targeting of KCa3.1 to the basolateral membrane (BLM) of polarized
epithelial cells is still emerging. Here, we examined the role of the cytoskeleton
(microtubules and microfilaments) and Myosin-Vc (Myo-Vc) in the targeting of KCa3.1 in
Fischer rat thyroid epithelial cells. We used a pharmacological approach with immunoblot
(for the BLM expression of KCa3.1), Ussing chamber (functional BLM expression of
KCa3.1) and siRNA experiments. The actin cytoskeleton inhibitors cytochalasin D (10
µM, 5 h) and latrunculin A (10 µM, 5 h) reduced the targeting of KCa3.1 to the BLM
by 88 ± 4 and 70 ± 5%, respectively. Colchicine (10 µM, 5 h) a microtubule inhibitor
reduced targeting of KCa3.1 to the BLM by 63 ± 7% and decreased 1-EBIO-stimulated
KCa3.1 K+ current by 46 ± 18%, compared with control cells. ML9 (10 µM, 5 h), an
inhibitor of myosin light chain kinase, decreased targeting of the channel by 83 ± 2%
and reduced K+ current by 54 ± 8% compared to control cells. Inhibiting Myo-V with
2,3-butanedione monoxime (10mM, 5 h) reduced targeting of the channel to the BLM
by 58 ± 5% and decreased the stimulated current of KCa3.1 by 48 ± 12% compared
with control cells. Finally, using siRNA for Myo-Vc, we demonstrated that knockdown of
Myo-Vc reduced the BLM expression of KCa3.1 by 44 ± 7% and KCa3.1 K+ current by
1.04 ± 0.14 µA compared with control cells. These data suggest that the microtubule
and microfilament cytoskeleton and Myo-Vc are critical for the targeting of KCa3.1.
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INTRODUCTION
The intermediate conductance, Ca2+-activated K+ channel (KCa3.1, KCNN4) is targeted to the
basolateral membrane (BLM) in polarized epithelial cells where it aids in maintenance of the
cellular potential required for normal cellular function (Devor et al., 1996; Ishii et al., 1997; Logsdon
et al., 1997; Vandorpe et al., 1998). Thus, KCa3.1 plays critical roles in epithelial ion and fluid
transport, cardiovascular and blood pressure regulation, endothelia function, and blood physiology
(Grgic et al., 2009; Köhler et al., 2010; Wulff and Castle, 2010).
In the last 20 years, KCa3.1 has emerged as a key therapeutic target for a number of diseases and
the modulation of this channel has been investigated in an attempt to develop therapeutic measures
for ameliorating diseases such as autosomal dominant polycystic kidney disease (Albaqumi et al.,
2008), vascular disease (Köhler, 2009; Damkjaer et al., 2012), and ulcerative colitis (Al-Hazza et al.,
2012). Due to the recent discovery of mutations in KCa3.1 (Rapetti-Mauss et al., 2015) associated
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with an autosomal-dominant form of anemia (hereditary
xerocytosis, Miller et al., 1971) the need to understand the role
of KCa3.1 in disease had come under scrutiny.
Interestingly, in therapeutic development, many steps have
been taken to regulate the K+ channel activity of KCa3.1
via pharmacological agonists or inhibitors (Wulff et al., 2001;
Bradding and Wulff, 2009; Köhler et al., 2010; Yu et al., 2013),
however, little research has been conducted to examine the
mechanism of how KCa3.1 is targeted to the plasma membrane.
Increased or decreased KCa3.1 activity can result in altered
pathophysiological states (Albaqumi et al., 2008; Al-Hazza et al.,
2012). Therefore, modulation of specific pathways in targeting
KCa3.1 to the BLMmay be a viable therapeutic approach.
Complex pathways ensure that apically and basolaterally
destined proteins are correctly sorted and targeted to the
appropriate membrane (Fölsch et al., 2009; Ang and Fölsch,
2012). As such, the cytoskeleton plays a significant role in the
targeting of membrane proteins. The microtubule cytoskeleton
is found throughout cells (Li et al., 2012) and it is composed of
polarized, dynamic, and hollow tube shaped structures formed
from tight helices of polymerized dimers of α and β tubulin
(Mitchison and Kirschner, 1984). The formation of microtubules
occurs via the polymerization of αβ-tubulin dimers that are
controlled by the hydrolysis of β-GTP to β-GDP (Brouhard
and Sept, 2012). The microtubule cytoskeleton has long been
investigated as playing a role in protein targeting. Using
pharmacological methods, themicrotubule cytoskeleton has been
implicated in the BLM targeting of proteins in epithelial cells
including aquaporin 4 (AQP4; Mazzaferri et al., 2013) and V-
ATPase (Brown et al., 1992).
Microfilaments (herein referred to as the actin cytoskeleton)
are conserved across cells and are comprised of dynamic
structures that play roles in trafficking, motility, stability, and
muscle contraction (Hightower and Meagher, 1986; Semenova
et al., 2008). Actin filaments (F-actin) consist of polymerized
G-actin monomers. G-actin binds the existing F-actin strand
via hydrolysis of G-(ATP)-actin monomers to G-(ADP)-actin
(Frixione, 2000; Oda and Maéda, 2010). The actin cytoskeleton
is associated with many accessory proteins, including Myosin Vc
(Myo-Vc; Jacobs et al., 2009). Myosins function as actin motor
proteins and bind actin filaments via cyclic phosphorylation
and hydrolyzation, producing forces, and directional mechanical
work in both muscle and non-muscle cells (De La Cruz et al.,
1999). 35 classes of myosins have been distinguished on the
basis of sequences of amino acids in their hydrolyzing domains
(Odrontiz and Kollmar, 2007; Kneussel and Wagner, 2013),
of these Myo-Vc was selected as a candidate gene. Myo-Vc is
highly expressed in exocrine and epithelial tissues (Rodriguez and
Cheney, 2002; Jacobs et al., 2009) and was chosen for this study,
because, this motor protein is important in organelle and vesicle
transport (Rosé et al., 2002; Desnos et al., 2007).
While Bertuccio et al. (2014) reported that Rab1 and Rab8
are important for the arrival of KCa3.1 to the BLM, little
more investigation has been conducted to further explore the
mechanism of the basolateral targeting of KCa3.1. In this study,
we have investigated the role of the cytoskeleton and Myo-Vc
in the basolateral targeting of KCa3.1 in a polarized epithelium.
Here, we provide the first evidence that the targeting of KCa3.1 to
the BLM is dependent on the microtubule and actin cytoskeleton,
and specifically the actin motor protein Myo-Vc.
MATERIALS AND METHODS
Molecular Biology
The biotin ligase acceptor peptide (BLAP) sequence
(GLNDIFFEQKIEWHE) was inserted into the second
extracellular loop of KCa3.1 as previously described (Balut
et al., 2010a; Gao et al., 2010). KCa3.1-BLAP and BirA (biotin
ligase) with an endoplasmic reticulum (ER) retention sequence,
KDEL (BirA-KDEL; kindly provided by Dr. Alice Ting,
Massachusetts Institute of Technology, Cambridge, MA, Chen
et al., 2005; Howarth and Ting, 2008), were subcloned into a
bicistronic plasmid, pBudCE4.1 (Invitrogen, ThermoFisher,
Waltham, MA, USA) behind the EF-1α and CMV promoters,
respectively (further details in Balut et al., 2010a,b; Gao et al.,
2010; Balut et al., 2011).
Cell Culture and Establishing a Stably
Transfected FRT Cell Line
Fisher rat thyroid (FRT) cells were cultured in Nutrient Mixture
F-12media (Invitrogen) and supplemented with 10% fetal bovine
serum and 1% penicillin-streptomycin (Life Technologies,
ThermoFisher). The cells were cultured in a humidified 5%
CO2/95% O2 incubator at 37
◦C. We established a stable cell
line by transfecting the bicistronic plasmid pBudCE4.1 dually
expressing KCa3.1-BLAP and BirA-KDEL with Lipofectamine
2000TM (Invitrogen) into FRT cells (FRT-KCa3.1-BLAP). Devor
and coworkers (Gao et al., 2010) have previously demonstrated
that insertion of the BLAP sequence into KCa3.1 did not affect the
Ca2+ sensitivity, activation by DCEBIO, or the inhibition of the
channel by clotrimazole. The stable cell line wasmaintained using
zeocin (850 µg/ml, Life Technologies; protocol approved by the
University of Otago Institutional Biological Safety Committee).
Stably transfected FRT-KCa3.1-BLAP cells were seeded on to
TranswellTM or SnapwellTM permeable supports (Corning Inc.,
Corning, NY) at a density of 5 × 105 cells and cultured to form
confluent epithelial monolayers (∼3 days) in a humidified 5%
CO2/95% O2 incubator at 37
◦C.
Biotinylation and Streptavidin Labeling of
KCa3.1-BLAP
Within the stable KCa3.1-BLAP—BirA-KDEL cell line, the BirA-
KDEL is retained within the ER, therefore, once a KCa3.1-BLAP
channel is assembled within the ER, the biotin ligase enzyme,
Bir-A, biotinylates the channel prior to exiting of the channel
from the ER, and being targeted to the plasma membrane.
Once at the plasma membrane, streptavidin labeling of surface
KCa3.1-BLAP was performed as previously described (Balut
et al., 2010a; Bertuccio et al., 2014). Briefly, upon reaching
confluence, cells were taken out of the incubator for labeling,
all procedures and solutions were maintained at 4◦C to prevent
channel internalization. Cells were first washed with 2ml of 4◦C
PBS with 1% bovine serum albumin (BSA) on both apical and
basolateral sides of the permeable support filter to eliminate
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residual media. Since streptavidin is cell impermeable, the cells
were labeled by applying streptavidin (10 µg/ml in PBS with 1%
BSA) on the desired side (apical or basolateral, depending upon
the experimental protocol) of the filter for 35min at 4◦C. After
labeling, cells were washed three times with PBS with 1% BSA
and three times with PBS to eliminate residue streptavidin and
the cells were incubated for various periods of time at 37◦C as
indicated in the text (Balut et al., 2010a; Bertuccio et al., 2014).
Reverse Transfection
FRT-KCa3.1-BLAP cells were reverse transfected (5 pmol) with
either the Myo-Vc siRNA plasmid (FRT-KCa3.1-BLAP+MyoVc-
siRNA; Thermo Fischer Scientific) or the Universal Negative
siRNA Control I plasmid (FRT-KCa3.1-BLAP+SC-siRNA;
Thermo Fischer Scientific) for 48 h using Lipofectamine 2000TM
(Invitrogen). FRT-KCa3.1-BLAP cells were seeded at a density
of 7.5 × 104 cells onto TranswellTM and SnapwellTM permeable
support filters (Corning Inc.) and cultured to form a confluent
epithelial monolayer in a humidified 5% CO2/95% O2 incubator
at 37◦C.
Cytotoxicity Tests
Cytotoxicity tests were conducted to determine the non-
toxic concentration of the drugs for normal cell growth and
integrity of FRT cells. Therefore, FRT-KCa3.1-BLAP cells were
treated with cytochalasin D (Cyto D), latrunculin A (Lat
A), ML9 [1-(5-Chloronaphthalene-1-sulfonyl)-1H-hexahydro-
1,4-diazepine hydrochloride], or colchicine at 0, 5, 10, and 20
µM for 0, 3, and 5 h. Likewise to assess the toxicity of 2,3-
butanedione monoxine (BDM), cells were treated with BDM
at 0, 5, 10, and 20mM for 0, 3, and 5 h. Normally, FRT-
KCa3.1-BLAP cells were seeded at a density of 5 × 105 cells
and cultured to confluence on TranswellTM filters and counted
post drug treatment with a haemocytometer at the designated
incubation time point. There was only cytotoxic effects of FRT
cells grown for the 5 h time point with 20 µM for Cyto D
(Supplementary Figure 1A), Lat A (Supplementary Figure 1B),
and colchicine (Supplementary Figure 1C) and no toxic effects
on FRT cell growth treated with ML9 or BDM for any
concentration or time point (data not shown). Therefore, 10
µM was used for examining the effect of Cyto D, Lat A, ML9,
colchicine, and 10mM BDM on the targeting of KCa3.1.
Antibodies
For the detection of Myo-Vc, goat polyclonal anti-Myo-
Vc [Myosin-Vc (Y-19): sc-160556] (1:1000) and HRP-linked
polyclonal donkey anti-goat IgG (1:10,000) were purchased from
Santa Cruz Biotechnology Incorporated (Santa Cruz, CA, USA).
HRP-linked polyclonal donkey anti-rabbit IgG (1:2000) was
purchased from Promega Corporation (Madison, WI, USA).
To detect KCa3.1, rabbit polyclonal anti-streptavidin (1:1000)
was obtained from GenScript (Piscataway, NJ, USA) and HRP-
linked polyclonal donkey anti-rabbit IgG (1:2000) was purchased
from Promega Corporation. For the detection of GAPDH, rabbit
polyclonal anti-GAPDH (1:1000) was purchased from Sigma-
Aldrich (St Louis, MO, USA).
Immunoblot Experiments
Cells were lysed and the protein was harvested as previously
described (Balut et al., 2010b, 2011; Gao et al., 2010) and protein
concentrations were determined by the BCA technique. 30 µg of
protein was run per lane with a protein standard (BenchMarkTM,
Invitrogen, Cat. No. 10748-010) added to a different lane and
separated out on an 8% SDS-PAGE gel, and gels were run on a
Hoefer Mighty Small II system (Cat. No. 80-6149-35, Amersham
Biosciences Corp. Piscataway, NJ, USA) at 150 V for 90min
or until the dye front reached the bottom of the gel. After
which, proteins were transferred onto a polyvinyl-diflouride
membrane (Sigma, St. Louis, MO, USA) using the Trans-Blot R©
TurboTM Transfer Starter System (Model 1704155, Bio-Rad,
Hercules, CA, USA) in transfer buffer (25mM Tris, 190mM
glycine, and 20% methanol) at 25 V for 30min. Membranes
were blocked overnight at 4◦C in a TBS-T blocking solution (5%
milk powder, 0.1% Tween 20). Membranes were then incubated
in 1◦ Ab for 1 h at room temperature for the detection of
either KCa3.1, Myo-Vc, or GAPDH (used as a loading control).
Membranes were then washed extensively in TBS-T (0.1% Tween
20) and incubated in the appropriate 2◦ Ab for 1 h at room
temperature. Membranes were then washed again in TBS-T
(0.1% Tween 20) and detection was performed using West Pico
Chemiluminescent Substrate (Roche Diagnostics, Indianapolis,
IN, USA). Immunoblot band densities for KCa3.1 and Myo-Vc
were normalized to the GAPDH loading control. All immunoblot
data were quantified using Image J (NIH, vers. 1.51, Bethesda,
MD, USA).
Ussing Chamber Experiments
For conductingUssing chamber experiments, FRT-KCa3.1-BLAP
cells were cultured on SnapwellTM filters and grown to form
a confluent monolayer. To facilitate a K+ gradient across the
monolayer and promote transepithelial K+ transport, the apical
(mucosal) chamber was filled with 5 ml of high K+ Ringer’s (in
mM) 145 potassium gluconate, 10 HEPES, 1 MgCl, 4 CaCl2, and
10 glucose (pH 7.4) and the basolateral (serosal) chamber was
filled with a solution containing (inmM) 140 sodium gluconate, 5
potassium gluconate, 10 HEPES, 1 MgCl, 4 CaCl2 and 10 glucose
(pH of 7.4). All solutions were maintained at 37◦C. The CaCl2
was increased from the normal 1.2–4mM to compensate for the
Ca2+-buffering capacity of the gluconate anion (Durham, 1983).
KCa3.1 activity was stimulated using KCa3.1 specific agonist 1-
EBIO (100 µM, Devor et al., 1996) and inhibited by clotrimazole
(10 µM, Devor et al., 1997). All measurements were recorded
by a VCC MC Ussing chamber system (Physiologic Instruments,
San Diego, CA, USA). The Ussing chamber was comprised of
an Easymount chamber system with 8-chamber voltage and
current units (Physiologic Instruments). Prior to mounting a
filter in a chamber, the Ussing chamber was zeroed to remove
any offsets (Clarke, 2009). The monolayer was considered to
have sufficient integrity when the FRT monolayer exhibited a R
> 500 ; therefore experiments where R did not achieve ≤500
 were not used for data analyses. Wild type FRT cells (WT)
served as controls for the Ussing experiments as seen for the
colchicine (Figure 4C) and ML9 (Figure 5C) experiments. The
slight changes in the current traces for the WT cells with the
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addition of 1-EBIO and clotrimazole were due to the vehicle
(ethanol) that was verified in vehicle control experiments (data
not shown).
Ussing chamber experiments were conducted to demonstrate
the specificity of clotrimazole for inhibiting 1-EBIO-stimulated
K+ current of KCa3.1 in our FRT-KCa3.1-BLAP stable cell
line. As can be seen in Supplementary Figure 2, 1-EBIO (100
µM) increased K+ current which was blocked by clotrimazole
(10 µM). The remaining basal current was blocked by barium
(10mM).
Chemicals
All chemicals were purchased from Sigma-Aldrich, unless
otherwise stated. DMSO was used as a vehicle for Cyto D, Lat
A, ML9, and BDM. The vehicle for colchicine, 1-EBIO, and
clotrimazole was ethanol.
Statistical Analyses
In this study “n” is indicative of the number of experiment
repeats for different passages of cells; P ≤ 0.05 was considered
statistically significant and all data are presented as mean ±
SEM. Cytotoxic tests were analyzed using the parametric one way
analysis of variance (one way ANOVA) followed by a Bonferroni
post-test. Recorded Ussing traces were analyzed using Microsoft
Excel (2010) and GraphPad Prism 5 (GraphPad Software, Inc.,
La Jolla, CA). A non-parametric Kruskal-Wallis with a Dunn’s
post-test was used to compare traces of 1-EBIO stimulated
KCa3.1 currents of Ussing chamber data were normalized to FRT-
KCa3.1-BLAP controls. To compare the normalized values of the
immunoblot band intensities, statistical analysis was performed
using the non-parametric Kruskal-Wallis test followed by a with
Dunn’s post-test. A one-way ANOVA followed by a Bonferroni
post-test was used to compare trace peaks of KCa3.1 current
in FRT-KCa3.1-BLAP, FRT-KCa3.1-BLAP+SC-siRNA, and FRT-
KCa3.1-BLAP+MyoVc-siRNA cell lines.
RESULTS
Localization of KCa3.1 in Polarized FRT
Cells
To verify the membrane localization of KCa3.1, FRT-KCa3.1-
BLAP cells were cultured on TranswellTM filters and labeled with
streptavidin at either the apical or basolateral membrane. This
was followed by immunoblot blot experiments using streptavidin
and GAPDH antibodies as described in the Section Materials
and Methods. As seen in Figure 1, KCa3.1 is expressed at the
basolateral membrane of polarized FRT-KCa3.1-BLAP cells with
no expression of the channel at the apical membrane (n = 4).
These results confirmwhat we have previously reported using the
FRT-KCa3.1-BLAP cell line (Bertuccio et al., 2014).
The Role of the Microfilament (Actin)
Cytoskeleton in the BLM Targeting of
KCa3.1
Microfilaments are comprised of actin and play an important role
in intracellular trafficking of proteins and trafficking proteins by
exocytosis and endocytosis (Conner and Schmid, 2003; Lee et al.,
1        2         3        
KCa3.1 (79kD)
GAPDH (37kD)
FIGURE 1 | Localization of KCa3.1 in stably transfected FRT cell line.
FRT-KCa3.1-BLAP cells were grown to confluence on TranswellTM filters. Lane
1: Negative control—non-labeled FRT-KCa3.1-BLAP cells. Lane 2: Apically
streptavidin labeled FRT-KCa3.1-BLAP cells of the stably FRT cell line. Lane 3:
Basolaterally-labeled FRT-KCa3.1-BLAP cells of the stably FRT cell line.
GAPDH was used as a loading control. This sidedness experiment confirms
that KCa3.1 is trafficked to the basolateral membrane of the stably transfected
FRT-cell line. Thirty micrograms of protein was loaded per lane (n = 4).
2008). Inhibitors of actin can modify polymerization of either F-
actin or G-actin cytoskeleton, thus, reducing protein transport
(Casella et al., 1981; Yarmola et al., 2000). We hypothesized that
interrupting actin formation would result in reduced targeting
of KCa3.1 to the BLM. Therefore, we tested whether Cyto D
that inhibits F-actin and Lat A that inhibits G-actin (Casella
et al., 1981; Yarmola et al., 2000) alter targeting of KCa3.1 to
the BLM. Therefore, immunoblot experiments were conducted
as described above. FRT-KCa3.1-BLAP cells were treated with
either Cyto D or Lat A at 10 µM for 0, 3, and 5 h. As can be
seen in Figure 2, FRT-KCa3.1-BLAP cells treated with Cyto D for
5 h exhibited a reduced BLM expression of KCa3.1 by 88 ± 4%
(P≤ 0.01) compared to untreated control cells (t = 0 h, n = 5).
A similar effect was observed in FRT-KCa3.1-BLAP cells treated
with Lat A (Figure 3) where there was a reduced BLM expression
of KCa3.1 by 70± 5% (P≤ 0.001) compared to untreated control
cells (t = 0 h, n = 5). These data demonstrate, for the first time,
that the targeting of KCa3.1 to the BLM of a polarized epithelium
is dependent upon the intact actin cytoskeleton.
The Role of the Microtubule Cytoskeleton
in the Targeting of KCa3.1
The role of the microtubule cytoskeleton has been documented
in the trafficking of basolateral membrane proteins such as AQP4
and the V-ATPase (Brown et al., 1992; Mazzaferri et al., 2013)
with using colchicine as an inhibitor of microtubule function.
Therefore, we examined the effects of colchicine on confluent
FRT-KCa3.1-BLAP cells to determine whether the microtubule
cytoskeleton is crucial in the targeting of KCa3.1 to the BLM.
The functional expression of KCa3.1 at the BLM was examined
with immunoblot and Ussing chamber experiments. Therefore,
FRT-KCa3.1-BLAP cells were seeded on to filters and incubated
with colchicine (10 µM) for 0, 3, and 5 h. As demonstrated by
immunoblot experiments (Figures 4A,B), at 5 h, the expression
of KCa3.1 at the BLM was reduced by 63 ± 7% (P ≤ 0.01,
n = 5) with respect to cells not treated with colchicine. To
examine the effects of colchicine on the functional expression
of FRT-KCa3.1-BLAP at the BLM, results from Ussing chamber
experiments demonstrated that FRT-KCa3.1-BLAP cells treated
with colchicine (for 5 h) had reduced K+ current (46 ± 18%,
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FIGURE 2 | The effect of cytochalasin D (Cyto D) on the targeting of
KCa3.1 to the BLM of FRT cells. (A) Immunoblot of KCa3.1 expression in
response to exposure to Cyto D: FRT-KCa3.1-BLAP cells were incubated with
Cyto D (10 µM) for 0, 3, and 5 h. Lane 1: untreated FRT-KCa3.1-BLAP cells,
t = 0 h. Lane 2: FRT-KCa3.1-BLAP cells + Cyto D, t = 3 h. Lane 3:
FRT-KCa3.1-BLAP cells + Cyto D, t = 5 h. GAPDH was used as a loading
control. (B) Immunoblot quantification indicated that Cyto D reduced KCa3.1
expression at the BLM by 88 ± 4% at t = 5 h with respect to t = 0 h, (n = 5,
**P ≤ 0.01). NS, not significant.
FIGURE 3 | The effect of latrunculin A (Lat A) on the targeting of KCa3.1
to the BLM of FRT cells. (A) Immunoblot of KCa3.1 expression in response
to exposure to Lat A: FRT-KCa3.1-BLAP cells were incubated with Lat A (10
µM) for 0, 3, and 5 h. Lane 1: untreated FRT-KCa3.1-BLAP, t = 0 h. Lane 2:
FRT-KCa3.1-BLAP+ Lat A, t = 3 h. Lane 3: FRT-KCa3.1-BLAP+ Lat A, t =
5 h. GAPDH was used as a loading control. (B) Immunoblot quantification
demonstrated that Lat A reduced KCa3.1 expression at the BLM by 70 ± 5%
at t = 5 h with respect to t = 0 h, (n = 5, ***P ≤ 0.001). NS, not significant.
P ≤ 0.05, n = 6) compared to untreated FRT-KCa3.1-BLAP cells
(Figures 4C,D, n= 6).
Collectively, these data provide the first experimental evidence
that colchicine, via potential disruption of microtubule structure,
reduced the BLM and functional expression of KCa3.1 of
polarized epithelial cells. As such, these data suggest that an intact
microtubule cytoskeleton is crucial for the proper targeting of
KCa3.1 to the BLM.
The Role of Light Chain Regulated Myosin
in the Targeting of KCa3.1
Since, we have established that the actin cytoskeleton is crucial
in the targeting of KCa3.1, our focus shifted to the potential
role of myosins in the targeting of KCa3.1. If a myosin is
critical in this process then our initial step was to determine
whether a myosin light chain kinase (MLCK) was involved in
the targeting of KCa3.1. This was investigated by using ML9, a
MLCK inhibitor (Ishikawa et al., 1988). Therefore, the role of
light chain regulated myosins in the targeting of KCa3.1 was
investigated by administering ML9 (10 µM) for 0, 3, and 5 h
to confluent FRT-KCa3.1-BLAP cells. Cells were seeded on to
filters for immunoblot and Ussing chamber experiments were
conducted as described above. As seen in Figures 5A,B, after
exposure to ML9 for 5 h, the BLM expression of KCa3.1 was
significantly reduced by 83 ± 2% (P ≤ 0.01) compared to cells
not incubated with ML9 (t = 0 h, n = 5). To determine the
effects of ML9 on the functional expression of KCa3.1, results
fromUssing chamber experiments (Figures 5C,D) demonstrated
that the inhibition of light chain kinase regulated myosins by
ML9 reduced K+ current of KCa3.1 by 54 ± 8% (P ≤ 0.001)
compared to control FRT-KCa3.1-BLAP cells (t = 0 h, n = 7).
The results demonstrate, for the first time, that the targeting of
KCa3.1 to the BLM of an epithelium is a light chain regulated
myosin-dependent mechanism.
The Role of Myosin-Vc in the Targeting of
KCa3.1 to the BLM
Having established a role of MLCK regulated myosins in the
targeting of KCa3.1, we next examined a myosin that might
participate in the BLM targeting of KCa3.1. Indeed, Myo-
Vc was selected as a possible motor protein as it is highly
expressed in epithelial tissues (Rodriguez and Cheney, 2002;
Jacobs et al., 2009). To carry out these experiments, 2,3-
butanedione monoxime (BDM) was chosen as an inhibitor of
Myo-V (Uemura et al., 2004). As above, the effects of BDM on
the targeting of KCa3.1 expression and membrane function were
examined as described above. The effect of the inhibition of Myo-
V on the expression of KCa3.1 was investigated by treating FRT-
KCa3.1-BLAP cells with BDM (10 mM) for 0, 3, and 5 h. After 5 h
exposure to BDM, the BLM expression of KCa3.1 was reduced
by 58 ± 5% (P ≤ 0.01) compared with untreated FRT-KCa3.1-
BLAP cells (Figures 6A,B, t = 0 h, n= 5). Similarly, results from
Ussing chamber experiments (Figures 6C,D) demonstrated that
BDM reduced the current of FRT-KCa3.1-BLAP cells by 48 ±
12% (P ≤ 0.01) compared with non-treated FRT-KCa3.1-BLAP
cells (t = 0 h, n= 8). These results suggest that Myo-V play a role
in the targeting of KCa3.1 to the BLM of epithelial cells.
In order to determine, indeed, that Myo-Vc plays a role in
the targeting of KCa3.1, Myo-Vc was targeted using a siRNA
approach. Therefore, FRT-KCa3.1-BLAP cells were transfected
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FIGURE 4 | The effect of colchicine on the BLM expression and function of KCa3.1. (A) Basolateral streptavidin was used to label KCa3.1 and incubated with
colchicine (10 µM) for 0, 3, or 5 h. Thirty micrograms of protein was run per lane. Lane 1: Untreated FRT-KCa3.1-BLAP, t = 0 h. Lane 2:
FRT-KCa3.1-BLAP+colchicine, t = 3 h. Lane 3: FRT-KCa3.1-BLAP+colchicine, t = 5 h. GAPDH was used as a loading control. (B) Immunoblot quantification, at t =
5 h, colchicine decreased KCa3.1 expression in FRT-KCa3.1-BLAP cells by 63 ± 7% relative t = 0 h (n = 5, **P ≤ 0.01). (C) A representative Ussing chamber trace of
FRT-KCa3.1-BLAP cells treated with colchicine (10 µM). KCa3.1 specific agonist 1-EBIO (100 µM) was applied once a stable baseline current was achieved resulting
in an increased K+ current. K+ current was inhibited by the addition of clotrimazole (10 µM). 1-EBIO elicited a significantly reduced K+ current in FRT-KCa3.1-BLAP
cells treated with colchicine (dashed line) compared to untreated FRT-KCa3.1-BLAP cells (solid line). This current was completely blocked by clotrimazole (10 µM). WT
FRT cells (WT, dotted line) served as controls and these cells exhibited no effect of 1-EBIO or clotrimazole. The minute change in current for WT was due to the vehicle
based on vehicle control experiments (data not shown). (D) Bar graph of K+ current peak of FRT-KCa3.1-BLAP cells and FRT-KCa3.1-BLAP+colchicine cells treated
with 1-EBIO. K+ current are normaiized to FRT-KCa3.1-BLAP cells. Colchicine decreased the 1-EBIO stimulated current by 46 ± 18% relative to FRT-KCa3.1-BLAP
cells. (n = 6, *P ≤ 0.05).
with either a universal negative control scrambled control
siRNA (FRT-KCa3.1-BLAP-SC) or Myo-Vc specific siRNA (FRT-
KCa3.1-BLAP-siRNA). Immunoblot data suggest that FRT-
KCa3.1-BLAP cells transfected with a Myo-Vc-siRNA had a
reduced cellular expression ofMyo-Vc andmembrane expression
of KCa3.1. Relative to control FRT-KCa3.1-BLAP cells, the
expression of Myo-Vc was reduced by 52 ± 11% (Figure 7A,
upper panel, and Figure 7B, P ≤ 0.05, n = 6) and membrane
expression of KCa3.1 was reduced by 44 ± 7% (Figure 7A,
middle panel, and Figure 7C, P ≤ 0.01, n = 6) in FRT-KCa3.1-
BLAP-siRNA cells, respectively. Relative to FRT-KCa3.1-BLAP-
SC cells, the expression of Myo-Vc and KCa3.1 was reduced by
73± 15% (Figure 7B, P ≤ 0.05, n= 6) and 46± 5% (Figure 7C,
P ≤ 0.05, n = 6) in FRT-KCa3.1-BLAP-siRNA cells, respectively.
Results from the Ussing chamber experiments corroborated the
immunoblot data in that in the presence of knockdown of
Myo-Vc, the K+ current of FTR-KCa3.1-BLAP-siRNA cells was
reduced by 1.04 ± 0.14 µA (dotted line, P ≤ 0.01, n = 6) with
respect to FRT-KCa3.1-BLAP cells (Figure 7D, solid line, and
Figure 7E). Relative to FRT-KCa3.1-BLAP-SC cells (Figure 7D,
dashed line), KCa3.1 specific K+ current was reduced by 0.7
± 0.2 µA (P ≤ 0.05, n = 6) in FRT-KCa3.1-BLAP-siRNA cells
compared to control SC cells (Figures 7D,E).
These results are the first to suggest that the targeting of
KCa3.1 to the BLM of epithelial cells is a Myo-Vc-dependent
process.
DISCUSSION
Our understanding of the targeting of KCa3.1 is still emerging.
Recently, Devor and colleagues made an important contribution
to this field by reporting that trafficking of KCa3.1 is a Rab1-
and Rab 8-dependent process (Bertuccio et al., 2014). Our results
advance the field by providing the first experimental evidence
that the microtubule and microfilament cytoskeleton and Myo-
Vc are critical for the targeting of KCa3.1 to the BLM of epithelial
cells.
The microtubules are considered an important component of
epithelial cells and colchicine has been employed to interrupt the
microtubule cytoskeleton in studying the basolateral trafficking
of proteins in epithelial cells (Brown et al., 1992). Therefore,
colchicine was used to examine the role of the microtubule
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FIGURE 5 | The effect of ML9 on the BLM expression and function of KCa3.1 in response to the inhibition of light chain kinase regulated myosins. (A)
Immunoblot of KCa3.1 expression in response to exposure to ML9. FRT-KCa3.1-BLAP cells were incubated with ML9 (10 µM) for 0, 3, or 5 h. Lane 1: untreated
FRT-KCa3.1-BLAP cells, t = 0 h. Lane 2: FRT-KCa3.1-BLAP+ML9, t = 3 h. Lane 3: FRT-KCa3.1-BLAP+ML9, t = 5 h. GAPDH was used as a loading control. (B)
Immunoblot quantification. ML9 reduced KCa3.1 expression at the membrane by 83 ± 2% t = 5 h with respect to t = 0 h, (n = 5, **P ≤ 0.01). (C) Ussing chamber
experiment with FRT-KCa3.1-BLAP cells with 5 h treatment of ML9 (10 µM). A standard trace is shown of ML9 treated and untreated FRT-KCa3.1-BLAP cells. 1-EBIO
elicited a significantly reduced K+ current in FRT-KCa3.1-BLAP cells treated with ML9 (dashed line) compared to untreated FRT-KCa3.1-BLAP cells (solid line). This
current was completely blocked by clotrimazole (10 µM). WT FRT cells (WT, dotted line) served as controls and these cells exhibited no effect of 1-EBIO or
clotrimazole. The minute change in current for WT was due to the vehicle based on vehicle control experiments (data not shown). (D) Bar graph of K+ current of
FRT-KCa3.1-BLAP cells and FRT-KCa3.1-BLAP+ML9 cells were treated with 1-EBIO. K+ current is normalized to FRT-KCa3.1-BLAP cells. ML9 decreased the
1-EBIO stimulated current by 54 ± 8% relative to FRT-KCa3.1-BLAP cells (n = 7, ***P ≤ 0.001).
function in the targeting of KCa3.1 to the BLM. Indeed,
colchicine reduced the functional expression of KCa3.1 at
the BLM of FRT-KCa3.1-BLAP cells (Figure 4). The reduced
basolateral delivery of KCa3.1 suggests that, similar to trafficking
of AQP4, the microtubule cytoskeleton is required for targeting
of the KCa3.1 (Mazzaferri et al., 2013). Interestingly, others
have described that the basolateral trafficking of Na+/K+-
ATPase (Boll et al., 1991) and A2R receptors (Saunders and
Limbird, 2000) are microtubule independent. This may suggest
that certain basolateral targeting pathways are microtubule-
dependent while others are not. It should also be noted that while
we have demonstrated a reduced BLM expression of KCa3.1 in
cells with compromised microtubule cytoskeleton, we are not
aware if KCa3.1 is mis-targeted to the apical membrane. Future
experiments investigating the potential apical mislocalization of
KCa3.1 with sidedness experiments (similar to Figure 1) would
address whether KCa3.1 is mis-targeted to the apical membrane
or retained within the cell. Nevertheless, the focus of this study
was on the basolateral targeting of KCa3.1, as such, those
experiments were outside the scope of the current study.
The Role of Myosin-Vc in the Targeting of
KCa3.1
It was important to determine if the actin cytoskeleton was
involved in the basolateral targeting of KCa3.1. Therefore,
experiments were conducted by depolymerizing the actin
cytoskeleton by administering Cyto D or Lat A to FRT-KCa3.1-
BLAP cells and examining the membrane expression of KCa3.1.
Immunoblot data demonstrated that FRT-KCa3.1-BLAP cells,
with compromised actin cytoskeleton, had a reduced expression
of KCa3.1 at the BLM relative to cells with an intact actin
cytoskeleton (Figures 2, 3). Following this, we examined the
role of actin motor proteins in the targeting of KCa3.1. We
selectedML9 to inhibit myosins containing light chains that were
regulated by MLCK (Ishikawa et al., 1988). Using immunoblot
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FIGURE 6 | The effect of BDM on the BLM expression and function of KCa3.1 in response to the inhibition of light chain kinase regulated myosins. (A)
Immunoblot of KCa3.1 expression in response to exposure to BDM. FRT-KCa3.1-BLAP cells are incubated with BDM (10 mM) for 0, 3, and 5 h. Lanes were loaded
with 30 µg of protein. Lane 1: FRT-KCa3.1-BLAP cells, t = 0 h. Lane 2: FRT-KCa3.1-BLAP+BDM, t = 3 h. Lane 3: FRT-KCa3.1-BLAP+BDM, t = 5 h. GAPDH was
used as a loading control. (B) Immunoblot quantification. At t = 5 h, BDM reduced KCa3.1 expression at the membrane by 58 ± 5% with respect to t = 0 h (n = 5,
**P ≤ 0.01). (C) Ussing chamber experiment of FRT-KCa3.1-BLAP cells with 5 h BDM treatment. A standard trace is shown of FRT-KCa3.1-BLAP cells and
FRT-KCa3.1-BLAP cells treated with 10mM BDM for t = 5 h. 1-EBIO generated a significantly reduced K+ current in FRT-KCa3.1-BLAP cells treated with BDM
(dashed line) compared to untreated FRT-KCa3.1-BLAP cells (solid line). This current was completely blocked by clotrimazole (10 µM). WT FRT cells (WT, dotted line)
served as controls and these cells exhibited no effect of 1-EBIO or clotrimazole (trace not shown due to clarity). (D) Bar graph of K+ current of FRT-KCa3.1-BLAP and
FRT-KCa3.1-BLAP+BDM cells treated with 1-EBIO. K+ current is normalized to data for FRT-KCa3.1-BLAP cells. BDM decreased the 1-EBIO stimulated current by
48 ± 12% relative to FRT-KCa3.1-BLAP cells. (*P < 0.05, n = 5) (**P ≤ 0.01, n = 8).
andUssing chamber experiments, we determined that when FRT-
KCa3.1-BLAP cells were exposed to ML9 there was a reduced
membrane and functional expression of KCa3.1 at the BLM
(Figure 5). These data demonstrate that the targeting of KCa3.1
to the BLM of polarized epithelial cells is dependent uponMLCK
regulated myosins.
There are 35 classes of myosins of which 13 are present
in humans and many of these myosins are MLCK regulated
(Odrontiz and Kollmar, 2007; Kneussel and Wagner, 2013). One
class of MLCK-regulated myosin is Myo-V; which is highly
expressed in epithelial tissues and involved in targeting of
organelles and vesicles containing cargo (Rodriguez and Cheney,
2002; Rosé et al., 2002; Desnos et al., 2007; Jacobs et al., 2009).
Therefore, initially, we inhibited Myo-V using BDM (Uemura
et al., 2004) to determine whether this myosin was involved in the
targeting of KCa3.1. Data from immunoblot and Ussing chamber
experiments demonstrated that BDM reduced themembrane and
functional expression of KCa3.1 at the BLM of FRT-KCa3.1-
BLAP cells (Figure 6). These data suggest that a Myo-V is
required for proper basolateral targeting of KCa3.1.
Several Myo-V isoforms has been reported (Nascimento et al.,
2013) and it has been established that the Myo-Vb is implicated
in the basolateral trafficking of voltage-gated K+ channel Kv1.5
(Schumacher-Bass et al., 2014). Interestingly, Myo-Vc is highly
expressed in epithelial (Rodriguez and Cheney, 2002; Jacobs
et al., 2009; Nascimento et al., 2013), and this motor protein
is known to interact with Rab8 (Jacobs et al., 2009; Xu et al.,
2009) which has been reported to play a role in the trafficking
of KCa3.1 in epithelial cells (Bertuccio et al., 2014). Endogenous
Myo-Vc was knocked down using a siRNA, approach. Based
on immunoblot and Ussing chamber experiments conducted on
matching passages of cells, a knock down of MyoVc (Figure 7B)
was achieved resulting in a corresponding reduced membrane
and functional expression of KCa3.1 at the BLM (Figures 7B–D).
Myo-Vc has been investigated in relation to the trafficking
pathways the polymeric immunoglobulin receptor (pIgR) and
viral interleukin 10 (vIL10) in the immortalized rabbit lacrimal
gland acinar cells (LGACs; Xie et al., 2009; Xu et al., 2013).
Studies suggest that in LGAC cells the exocytosis of pIgR and
vIL10 is dependent on Myo-Vc activity because when Myo-Vc
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FIGURE 7 | The membrane expression and function of KCa3.1 in response to the siRNA knockdown of Myosin-Vc. FRT-KCa3.1-BLAP were reverse
transfected (5 pmol) with a scrambled siRNA (FRT-KCa3.1-BLAP-SC) or siRNA to knock down MyoVc (FRT-KCa3.1-BLAP-siRNA). (A) FRT-KCa3.1-BLAP-SC, and
FRT-KCa3.1-BLAP-siRNA cells were run on an immunoblot. Lanes were loaded with 30 µg of protein. MyoVc and KCa3.1 were detected in FRT-KCa3.1-BLAP cells.
Lane 1: FRT-KCa3.1-BLAP, Lane 2: FRT-KCa3.1-BLAP-SC, and Lane 3: FRT-KCa3.1-BLAP-siRNA. GAPDH was used as a loading control. (B) MyoVc expression in
FRT-KCa3.1-BLAP-siRNA cells was reduced by 52 ± 11% (n = 6, *P ≤ 0.05) with respect to FRT-KCa3.1-BLAP cells. (C) In the presence of knockdown of Myo-Vc,
the KCa3.1 membrane expression in FRT-KCa3.1-BLAP-siRNA cells was reduced by 44 ± 7% (P ≤ 0.01) with respect to FRT-KCa3.1-BLAP cells. (D) Ussing
chamber experiment of FRT-KCa3.1-BLAP cells with Myosin-Vc knock down. Representative traces of FRT-KCa3.1-BLAP cells (solid line), FRT-KCa3.1-BLAP-SC
(dashed line) and FRT-KCa3.1-siRNA cells (dotted line) are shown. 1-EBIO promoted a significantly reduced K+ current in the FRT-KCa3.1-BLAP-siRNA cells
compared to FRT-KCa3.1-BLAP cells or the FRT-KCa3.1-BLAP-SC. This current was abated by clotrimazole (10 µM). (E) Bar graph of K+ current of
FRT-KCa3.1-BLAP, FRT-KCa3.1-BLAP-SC, and FRT-KCa3.1-siRNA cells were treated with 1-EBIO. FRT-KCa3.1-BLAP-SC cells did not exhibit K+ current different
relative to FRT-KCa3.1-BLAP cells (n = 6, P > 0.05). FRT-KCa3.1-BLAP-siRNA cells demonstrated a current significantly reduced by 1.04 ± 0.14 µA (*P ≤ 0.01) with
respect to FRT-KCa3.1-BLAP cells, and a K+ current significantly reduced by 0.7 ± 0.2 µA (*P ≤ 0.05) with respect to FRT-KCa3.1-BLAP-SC cells was also
recorded. (n = 6, **P < 0.01) (n = 6, *P ≤ 0.05).
was inhibited there was a reduction in the exocytosis of pIgR and
vIL10 in LGACs (Xie et al., 2009; Xu et al., 2013). These data are
similar to what we report in this study, suggesting that Myo-Vc is
important for targeting of KCa3.1 to the BLM.
However, these findings come with a caveat. While we
understand that targeting of KCa3.1 is dependent on Myo-
Vc, we are unsure of the exact role Myo-Vc plays. KCa3.1
transport from the Golgi to the BLM is a Rab 8-dependent
process (Bertuccio et al., 2014). Rab 8 has been reported to
interact with both the actin cytoskeleton and Myo-Vc (Chabrillat
et al., 2005; Watanabe et al., 2008; Xu et al., 2009), and as
the protein modulates cargo transport between the Golgi and
BLM, it is plausible that Myo-Vc also plays a role in cargo
transport in this cellular region. However, Myo-Vc has been
found to also traffic cargo along microtubules (Jacobs et al.,
2009), therefore it is possible that this motor protein transports
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KCa3.1 along the microtubule cytoskeleton and onto the actin
cytoskeleton.
It is also possible that the exocyst may provide this link
between the microtubule cytoskeleton and the actin filaments.
The exocyst is an octomeric protein complex important for
basolateral trafficking in epithelial cells forming a “tether”
complex at the BLM (Hsu et al., 2004). Exocyst components
Sec6/8 are also involved in the formation of basolateral targeted
vesicles (Yeaman et al., 2001). Additionally, the exocyst complex
is involved in the targeting and tethering of basolaterally destined
vesicles post-Golgi to the membrane, prior to the fusion of the
vesicle with the membrane (Munson and Novick, 2006; He and
Guo, 2009). Interestingly, we have already demonstrated that the
microtubule cytoskeleton is important in the targeting of KCa3.1
and the exocyst complex interacts directly with the yeast Myo-
V isoform Myo2p (Reck-Peterson et al., 1999) in the transport of
secretory vesicles (Jin et al., 2011). The exocyst also plays a critical
role in the development of the microtubule cytoskeleton (Wang
et al., 2004) with tubulin polymerization and vesicle targeting to
the plasmamembrane being reduced in epithelial and neural cells
when in exocyst complex is inhibited (Vega andHsu, 2001;Wang
et al., 2004). While this is an unexplored avenue of research it is
possible that the exocyst plays an important role in the targeting
of KCa3.1, and thus, this warrants further investigation.
Here, we have provided the first evidence that Myo-Vc is
critical in the targeting of KCa3.1. Expression and functional
studies were employed to investigate both the role of the
microtubule and actin cytoskeleton and the motor protein Myo-
Vc in the targeting of KCa3.1 to the BLM of polarized epithelial
cells. Using pharmacological inhibitors and siRNA techniques
it was determined that the basolateral targeting of KCa3.1 in a
polarized epithelium is a microtubule, actin microfilament, and
Myo-Vc dependent process.
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Supplementary Figure 1 | The cytotoxic effects of cytochalasin D (Cyto D),
latrunculin A (Lat A), and colchicine on FRT cells. (A) Cytotoxic effects of
Cyto D on confluent FRT-KCa3.1-BLAP cells at 0, 1, 10, and 20 µM were tested
over a 5 h time period at incubation intervals of 0, 3, and 5 h at 37◦C. Cyto D at 20
µM for t = 5 h reduced FRT-KCa3.1-BLAP cell population from 2.1 × 106 ± 3.8
× 105 cells to 1.5 × 105 ± 2.2 × 105 cells (n = 4, ∗∗∗∗P < 0.0001). (B) Cytotoxic
effects of Lat A on confluent FRT-KCa3.1-BLAP cells at 0, 1, 10, and 20 µM
tested incubation times of 0, 3, and 5 h at 37◦C. Lat A at 20 µM for t = 5 h
reduced FRT-KCa3.1-BLAP cell counts from 2.8 × 106± 5.2 × 105 cells to 2.0 ×
106 ± 9.4 × 105 cells (n = 4, ∗∗∗∗P < 0.0001). (C) Cytotoxic effects of colchicine
at 0, 5, 10, and 20 µM on FRT-KCa3.1-BLAP cells were tested over a 5 h period
at incubation intervals of 0, 3, and 5 h at 37◦C. Colchicine at 20 µM for t = 5 h
reduced FRT-cell population from 2.0 × 106 ± 2.0 × 105 cells (t = 0 h) to 4.8 ×
105 ± 5.2 × 104 cells (t = 5 h, n = 4, ∗∗∗∗P < 0.0001).
Supplementary Figure 2 | Representative trace of the effects of 1-EBIO,
clotrimazole, and barium on K+ current of FRT-KCa3.1-BLAP cells.
FRT-KCa3.1-BLAP cells were seeded at a density of 500,000 cells and grown for
72 h on a Snapwell
TM
insert. Application of 1-EBIO (100 µM) to the
FRT-KCa3.1-BLAP cells stimulated a K+ current. Once the activated K+ current
was stable, addition of clotrimazole (10 µM) reduced all of the 1-EBIO-stimulated
current. The remaining basal current was decreased to 0 µA with the addition of
BaCl2 (10 mM; n = 2).
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